COMP <GO>
NNVC vs NSRX // REVENUE GROWTH (YOY)
NanoViricides Inc. (NYSE) VS. Nasus Pharma Ltd. (NYSE) • 15-METRIC TALLY: NNVC 1
— NSRX 2
■ METRIC PARITY
LAST: $1.43 (-1.38%) • MKT CAP: $36.5M
revenue-growth
—
LAST: $3.19 (-4.49%) • MKT CAP: $37.4M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNVC VS. NSRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNVC | NSRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -23.37% | -13.20% | -10.17 | NSRX | /fcf-yield <GO> |
| Operating Margin | — | -0.40% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -0.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 38.3 | +8.77 | NNVC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.5M | $37.4M | -$836.1K | NSRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNVC REV | NSRX REV | NNVC GROSS % | NSRX GROSS % | NNVC FCF | NSRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.24B | — | — | -$8.5M | -$4.9M |
| FY 2024 | $0 | $0 | — | — | -$6.5M | -$665.0K |
| FY 2023 | $0 | $0 | — | — | -$5.7M | -$1.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNVC // BETA —
NSRX // BETA —